{"symbol":"BMY","fiscalQuarter":"Q2-2018","reportDate":"2018-07-26","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2018","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 1.9%","keyNumbers":[{"metric":"EPS","actual":"$1.01","expected":"N/A","surprise":"+13.95%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in their key drug segments.","They expressed confidence in ongoing clinical trials and pipeline developments."],"summary":"Overall, management conveyed a sense of optimism regarding their drug portfolio. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a solid EPS beat, which indicates strong underlying performance. However, the stock declined by 1.9%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more comprehensive information on the company's future prospects.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2018 earnings: EPS beat by 13.95%. Stock down 1.9%. Full breakdown."}}